# HexemBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hexembio

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.hexemb.io/
- Total disclosed funding: $10M
- Latest round: Seed (Apr 6, 2026)
- Investors on record: 3

## About

Based in New York, US and co-founded in 2024 by Gabriel Levesque Tremblay (CEO), Samira Kiani (CTO), Mo Ebrahimkhani (CSO), Samet Yildirim (CBO), and Joshua Hislop, HexemBio Inc. is a biotechnology company developing regenerative therapies designed to rejuvenate aging blood-forming stem cells using its Synthetic Human Yolk Sac platform. In September 2026, HexemBio Inc. raised USD 15.5 million in venture funding lead by Draper Associates and Boost VC with participation from Happiness Capital, Korea Investment Partners, Seraphim Space Manager and SOSV.

Hexem Bio specializes in innovative stem cell therapy, particularly focusing on rejuvenating aged Hematopoietic Stem Cells (HSCs) to restore their youthful functionality. Their core offering is the Rejuvenated Stem Cell Therapy, which aims to enhance the production of healthy blood cells, including stronger white blood cells for improved immunity, red blood cells for better organ health, and increased platelet production for faster recovery. The therapy employs the Yolk Sac Method to access the early developmental state of HSCs, validated through extensive animal studies. Target markets include healthcare facilities and research institutions that cater to patients in need of advanced regenerative therapies, primarily in North America and parts of Europe.
Hexem Bio's revenue model revolves around partnerships with healthcare providers and research institutions that implement their stem cell therapies. Transactions are structured as direct sales or partnerships, granting clients access to the Rejuvenated Stem Cell Therapy as a specialized service. The company collaborates directly with medical facilities to establish agreements that outline service delivery and pricing, which reflect the advanced nature of the therapy and tailored client solutions.

The company plans to use the September 2026 funding to advance its stem cell rejuvenation platform, progress its bone marrow transplant therapy toward human clinical trials, and develop its injectable and skin treatment products.

## Funding rounds

- Seed, Apr 6, 2026, $10M — Seraphim Space Manager, SOSV, Draper
- Seed, Feb 14, 2025 — SOSV

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed
- Seraphim Space Manager (https://capitalatlas.ai/funds/seraphim-space-manager) — Seed
- Draper (https://capitalatlas.ai/funds/draper) — Seed